Metroka CE, Josefberg H; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 381 (abstract no. 2111).
St. Luke's/Roosevelt Hospital Center, New York, New York, USA
OBJECTIVE: An open study of the efficacy and tolerance of high dose acyclovir. METHODS: We studied 120 patients who were at high risk for CMV from 12/87 to 1/90. All patients had less than 150 CD4+ cells/mm3. Preliminary data analysis is presented. RESULTS: The mean CD4+ cells at the time of treatment initiation was 64 (range, 4 to 146). The mean duration of follow-up was 15.5 mos (range, up to 24 mos). 2/120 pts receiving acyclovir 800 mg po 5x/day (4.0 grams/day) developed invasive CMV. Both pts were subsequently treated with ganciclovir and 1 died of progressive, disseminated CMV 12 wks after diagnosis. 0/120 pts receiving acyclovir developed Herpes simplex or Herpes zoster and there was clearing of hairy leukoplakia in all 16 patients who presented with hairy leukoplakia. 1 pt developed CMV retinitis after discontinuation of acyclovir for 4 wks. Side effects included nausea and vomiting in 4 pts and pain at the site of prior Herpes zoster in 1 pt. Dose reduction by half in 5 pts led to invasive CMV in 3 pts. 34 pts receiving high dose acyclovir developed other OI's or malignancies; 20 have died; death was due to CMV in 1 of the prophylaxis failures. In contrast 9 of 14 pts who refused treatment developed invasive CMV. CONCLUSION: This study strongly suggests that acyclovir is useful as prophylaxis of CMV, Herpes simplex, and Herpes zoster, as well as clearing of hairy leukoplakia.
Publication Types:
Keywords:
- Acyclovir
- CD4-Positive T-Lymphocytes
- Ganciclovir
- Herpes Simplex
- Herpes Zoster
- Humans
- Immunization, Passive
- Kidney Transplantation
- Leukoplakia, Hairy
- Liver Transplantation
- prevention & control
- surgery
- therapy
- transplantation
Other ID:
UI: 102197118
From Meeting Abstracts